Biologics receives National Comprehensive Cancer Network recognition

Biologics, Inc., an oncology management company, has been recognized by the National Comprehensive Cancer Network^® (NCCN^®) for its commitment to supporting patient access to quality oncology care. For the first time, the NCCN, a not-for-profit alliance of 21 of the world's leading cancer centers, is recognizing commercial payor and non-payor organizations, including Biologics, which support the appropriate, effective, and efficient use of oncology treatment and care of patients through its new NCCN Recognition Program.

"Biologics has shown its commitment, through both words and actions, to helping ensure that individuals with cancer have access to high quality, evidence-based care and to clinical trials," said Liz Danielson, Director of Payor Relations for NCCN. "We appreciate their leadership in this area."

NCCN's new program recognizes managed care organizations (MCOs) that establish and follow policies which cover both the routine costs of care for individuals enrolled in approved clinical trials, as well as the appropriate off-label use of approved drugs in oncology. In addition to MCOs, the program also recognizes non-payor organizations such as those that provide case management, patient management, and other services that make good faith efforts to educate their clients about these issues. Biologics is one of the first non-payor organizations to meet requirements for recognition.

"It's an honor to be recognized by NCCN. Over the last 17 years the foundation of our company has been centered on patient access. Everything we do, every decision we make is aimed at delivering care with the patient's best interest at heart. If we do that, all other matters will fall into place," said Stuart Frantz, President and Chief Executive Officer of Biologics.

NCCN develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™), which are evidence-based guidelines integrated with expert medical judgment detailing the sequential management decisions and interventions for the malignant cancers that affect 97 percent of all patients with cancer. The NCCN Guidelines™ strongly support participation in clinical trials and include recommendations of innovative drugs and biologics with indications that are supported by evidence and compendia, but are beyond the indications listed in the FDA label.

"One of the most important aspects within our care continuum model is to serve as a clinical resource to our clients in a rapidly changing field. We are fiercely determined to serve patients with compassion and excellence," said Ann Steagall, RN, BSN, OCN, Director of Clinical Operations, Oncology Management Services Group at Biologics. "To that end, we take our role very seriously to provide guidance on appropriate access to clinical trials and off-label uses of approved drugs. We are thrilled to be recognized by NCCN."

Through its oncology management program, Biologics is demonstrating that by providing a singular voice for patients throughout their plan of treatment and ensuring the most appropriate care, utilization and costs can be compressed.